Media Library
icon
-
ImagelockLocations / ImageOutside meeting space on Novartis Campus Basel
One of many inspiring work environments on Novartis Campus Basel. -
ImagelockLocations / ImageView of Fabrikstrasse 15, Novartis Campus Basel
-
ImagelockLocations / ImageView of Forum 1 and Fabrikstrasse, Novartis Campus Basel
-
VideolockCorporate Responsibility / B RollNovartis Animated Logo
-
VideolockManufacturing / B RollNIBR Cambridge, United States
-
VideolockManufacturing / B RollNIBR Basel
-
VideolockDisease Awareness / VideoManaging the TSC Transition to Adult Care
Ann describes how to live with symptoms as an adult living with Tuberous Sclerosis Complex (TSC) . -
ImagelockLeadership / ImageRob Kowalski
Chief People & Organization Officer since September 1, 2021│Member of the Executive Committee -
PDFlockProducts / Infographic
Interleukin 17-A (IL-17A) in Psoriasis
A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases. -
PDFlockProducts / Infographic
Interleukin 17-A (IL-17A) in Inflammatory Joint Disease
IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development. -
ImagelockProducts / Image
Kymriah® (tisagenlecleucel) suspension for intravenous infusion
Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019. -
PDFlockProducts / Fact Sheet
RTH258 Brolucizumab Clinical Trials
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.